Bayer's Portfolio Reshuffle: A €375 Million Exit, a Decade-Long Blockbuster Bet, and the Legal Overhang Still in Play
Published on 09/23/2026 at 16:50 | Editorial boerse-global.de
Bayer is simultaneously shedding mature assets and betting on a pipeline it hopes will define the next decade. The Leverkusen-based life sciences group has agreed to sell the worldwide rights to its established cancer drug Stivarga, whose active ingredient is regorafenib, to fellow German pharmaceutical company Grünenthal for as much as €375 million. The medicine is approved in more than 90 markets and is used against advanced colorectal, liver and gastrointestinal tumours.
Completion of the agreement is targeted for late 2026 or early 2027, and remains subject to merger control clearance. Investors took the news in stride rather than with enthusiasm. The stock was quoted at €49.87 on the day, a gain of 1.1%.
The disposal marks the opening move in a broader portfolio clean-up. Management intends to channel the freed-up capital more precisely into research and higher-growth products, and the market's task now is to judge how durably that restructuring strengthens the earnings profile.
Trading predictable cash flows for pipeline optionality
At the heart of the debate is whether Bayer can replace reliable revenue that is walking out the door. Stivarga is a mature product whose patent protection expires in the European Union in 2029 and in the United States in 2030. Aachen-based Grünenthal expects the business to contribute a positive operating result of up to roughly €100 million from 2027 onwards.
That figure illustrates just how profitable the drug remains even with generic competition on the horizon. By handing over those earnings, Bayer increases its dependence on research projects that have yet to be completed. Should development candidates stall in clinical trials or stumble at the approval stage, the company faces a lean stretch before new therapies generate meaningful sales.
Should investors sell immediately? Or is it worth buying Bayer?
Regulatory uncertainty adds a second layer of risk. If antitrust authorities withhold approval or attach conditions to the deal, the proceeds could come in lower or the closing could slip.
A ten-year, ten-blockbuster ambition
The divestment has to be read against an aggressive growth agenda. Bayer aims to bring ten potential blockbuster medicines to market within a decade, with two of those high-revenue products already in commercialisation according to company statements and further launches in preparation.
The pharmaceutical division has logged concrete milestones in the US recently. On 17 September, the FDA granted approval for finerenone under the brand name Kerendia for the treatment of adults with chronic kidney disease associated with type 1 diabetes. Bayer describes it as the first FDA-approved therapy for this specific condition in more than three decades.
Earlier in the month, on 9 September, the agency issued an accelerated approval for sevabertinib. The oncology drug was cleared as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer who carry specific activating mutations. The approval covers patients with non-squamous tumours and widens the company's oncology footprint.
Crop science builds its own pipeline
The agricultural arm is being reshaped in parallel. More than 15 new modes of action are in early-stage research within Crop Science, driven largely by the company's in-house, digitally supported research platform CropKey, which is designed to identify new crop protection molecules in a targeted way.
Legal legacy still shapes the valuation
On the group level, working through litigation remains a defining factor for how the shares are priced. Bayer subsidiary Monsanto has filed for court approval of a settlement in the US legal dispute over the herbicide Roundup, according to Reuters. A final and binding conclusion to those settlements is regarded by the capital markets as a decisive precondition for a sustainable re-rating of the Leverkusen group.
Bayer at a turning point? This analysis reveals what investors need to know now.
Sentiment has nonetheless improved. The stock is up 34% since the start of the year, and it sits 8.1% below its 52-week high of €53.86. A separate legal relief arrived in the summer: the US Supreme Court's ruling of 25 June, which shields Bayer from claims that it failed to warn of cancer risks on its weedkillers in the United States, has defused a central legal risk. The roughly 35% share price gain since the beginning of the year reflects that gradual de-risking.
What has to go right from here
For the share price, the regulatory execution and the future use of proceeds matter most. As long as the antitrust reviews proceed on schedule and the transaction closes by early 2027, management keeps the initiative in reshaping the portfolio. If clearance falls through or the drug pipeline succession stalls, doubts about the future earnings trajectory are likely to resurface.
The next concrete catalyst for investors is the antitrust decision on the Stivarga sale in the coming months. Ahead of the planned finalisation around the turn of 2026/2027, Bayer must also demonstrate how the released research funds are actually advancing the pipeline. Only then will it become clear whether swapping existing earnings for future promise pays off for shareholders. How quickly the new active ingredients from pharmaceuticals and agriculture deliver their expected revenue contributions will determine whether the long-term margin targets are reached.
Ad
Bayer Stock: New Analysis - 23 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
